Systemic treatment of tenosynovial giant cell tumours in context
Mené sur 120 patients atteints d'une tumeur à cellules géantes de la gaine tendineuse de stade avancé, cet essai de phase III évalue l'efficacité, du point de vue du taux de réponse globale en semaine 25, et la toxicité du pexidartinib, un inhibiteur de CSF1
Tenosynovial giant cell tumours (TGCTs) are a rare family of proliferative and inflammatory tumours, mostly affecting young adults. These tumours are benign lesions arising from the synovium, bursae, or tendon sheaths, and present either as a single nodule (localised type) or as multiple nodules (diffuse type). Previously, these tumour types were classified as pigmented villonodular synovitis or giant cell tumour of the tendon sheath. In the most recent version of the WHO classification of tumours of soft tissue and bone, it has been suggested that TGCT replaces both designations. Clinically, TGCTs can have a range of behaviours, from favourable to locally aggressive, and can consequently have a major effect on daily life.
The Lancet , commentaire, 2018